Back to Search
Start Over
Hydration requirements in patients receiving highly emetogenic chemotherapy.
- Source :
- Future Oncology; Mar2019, Vol. 15 Issue 7, p753-761, 9p
- Publication Year :
- 2019
-
Abstract
- <bold>Aim: </bold>Chemotherapy-induced nausea and vomiting diminishes quality of life and increases healthcare resource use. This retrospective medical records analysis evaluated hydration requirements with emetogenic chemotherapy.<bold>Patients& Methods: </bold>Cancer patients received moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC), and antiemetics palonosetron or granisetron extended-release subcutaneous (GERSC), neurokinin 1 receptor antagonist and dexamethasone. Unscheduled hydration event rates were determined.<bold>Results: </bold>For 186 patients (92 palonosetron, 94 GERSC) overall, mean hydration rate was significantly higher with palonosetron (0.6 vs 0.2; p = 0.0005). Proportion of patients with ≥1 hydration event was significantly higher with palonosetron overall (54 vs 33%; p = 0.0033) and in cycles 2-4 and the HEC subgroup.<bold>Conclusion: </bold>GERSC within a three-drug antiemetic regimen may reduce unscheduled hydration requirements with MEC or HEC. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14796694
- Volume :
- 15
- Issue :
- 7
- Database :
- Complementary Index
- Journal :
- Future Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 135139772
- Full Text :
- https://doi.org/10.2217/fon-2018-0787